ResMed (RMD) director granted 1,331 stock options at $250.52

ResMed Inc. (RMD) reported that one of its directors received a grant of 1,331 stock options on ResMed common stock with an exercise price of $250.52 per share.

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported that one of its directors received a grant of 1,331 stock options on ResMed common stock with an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date, and expire on November 11, 2032.

After this reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, as well as 1,331 stock options directly.

Insider Trade Summary

Grant/Award: 1,331 shares

Grant/Award 2 txns

Insider FARRELL PETER C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock Options	1,331	$250.52	$333K
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 1,331 contracts (Direct); ResMed Common Stock — 70,773 shares (Direct)

Footnotes (1)

1. F1. Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) report on this Form 4?

The filing reports that a ResMed Inc. director received a grant of 1,331 stock options on ResMed common stock.

What is the exercise price of the stock options granted to the ResMed (RMD) director?

The director’s stock options have an exercise price of $250.52 per share of ResMed common stock.

When do the new ResMed (RMD) stock options vest and become exercisable?

The options vest and become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders of the company following the grant date.

When do the ResMed (RMD) director’s stock options expire?

The stock options reported in the Form 4 expire on November 11, 2032.

How many ResMed (RMD) shares does the director own after this transaction?

Following the reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, plus 1,331 stock options directly.

What is the relationship of the reporting person to ResMed (RMD)?

The reporting person is identified as a director of ResMed Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 03:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock								70,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$250.52	11/24/2025		A		1,331		11/11/2026(1)	11/11/2032	ResMed Common Stock	1,331	$250.52	1,331	D

Explanation of Responses:

1. Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.

	/s/ Michael J. Rider, attorney-in-fact for Mr. Farrell	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.